Benign paroxysmal tonic upgaze of infancy: 2 additional cases]

Benign paroxysmal tonic upgaze is an ill-defined neuro-ophthalmological disorder with onset in infancy. It consists of sudden ocular movements with sustained upward deviation of the eyes. Episodes disappear with time: spontaneous remission occurs within a few months or years without any change in psychomotor development. EEG and neuro-imaging are unrevealing. To date, the pathogenesis of the condition is still unknown. Early recognition of this benign condition minimizes potentially unnecessary investigations and treatments. Herein, we report on 2 additional sporadic cases.     

Risikoanalyse und präoperative Prophylaxemaßnahmen

Zusammenfassung Probleml?sungsstrategien zu perioperativen Prophylaxema?nahmen umfassen mehr Studienarten als Tierexperimente und kontrollierte klinische Studien. Dabei verhelfen Methoden der kognitiven Psychologie und künstlichen Intelligenz zu neuen Verfahren, um kontroverse Standpunkte in der klinischen Versorgung zu formalisieren. Der Weg vom Tierexperiment zur klinischen Indikation, mag mühevoll und beschwerlich sein, aber die Strategie hat sich bei der perioperativen Antihistaminikaprophylaxe als eine neue Form der Prophylaxe schon bew?hrt. Gerade wurde im Refresher Course der ASA, der amerikanischen Gesellschaft für An?sthesie und Intensivmedizin, diese Prophylaxe für alle US-An?sthesisten empfohlen. Mit Unterstützung durch die Deutsche Forschungsgemeinschaft (Lo 199/16-2).     

Depressed antigen presentation function and membrane interleukin-1 activity of peritoneal macrophages after laparotomy

Although major tissue trauma produces profound depression of cell-mediated immunity, it is not known whether surgical trauma (i.e., midline laparotomy) has any adverse effect on the antigen presentation function and membrane interleukin-1 (IL-1) activity of peritoneal macrophages. To study this, C3H/HEJ (endotoxin-tolerant) mice were anesthetized. An approximately 1-inch midline abdominal incision was made, followed by abdominal closure. On days 1, 3, 5, and 7, peritoneal macrophages were harvested by means of peritoneal lavage, and antigen presentation capability was tested by incubating various numbers of peritoneal macrophages with 2 X 10(4) D10.G4.1 cells per well in the presence of conalbumin (400 micrograms/ml). The T helper cell clone (D.10.G4.1) proliferates on recognition of conalbumin in the context of Iak and also proliferates in the presence of membrane-bound IL-1 plus concanavalin A. To measure membrane IL-1 expression in peritoneal macrophages, Concanavalin A (10 micrograms/ml) was substituted for conalbumin. Cultures were incubated for 72 hours, pulsed with tritiated thymidine, and harvested. Peritoneal macrophages from laparotomized mice induced significantly less T helper cell proliferation on days 1 and 3 in the antigen presentation assay (37% and 30%, respectively; p less than 0.05) and in the membrane IL-1 assay (14% and 10%, respectively; p less than 0.05) as compared with the control. This difference was not detectable on day 5. More effective antigen presentation capability (167% of control; p less than 0.05) was seen on day 7. Thus laparotomy by itself produces marked depression of both antigen presentation function and membrane IL-1 activity of peritoneal macrophages, which may enhance susceptibility to intra-abdominal sepsis.     

Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy

Stroke is a major health problem worldwide, causing high morbidity and mortality. Intracerebral hemorrhage (ICH) accounts for 15% of stroke cases in the US and Europe and up to 30% in Asian populations. It is less treatable than other forms of stroke and causes higher morbidity and disability. Data suggest that early hematomy growth is the principal cause of early neurological deterioration after ICH. Prospective and retrospective studies indicate that early hematoma growth occurs in 18–38% of patients scanned within 3 h of ICH onset, and that hematoma volume is an important predictor of 30-day mortality. As hematoma growth in acute ICH is a dynamic process, intervention with ultra-early hemostatic therapy could lead to minimization and even prevention of early hematomy growth. Recombinant activated factor VII (rFVIIa, ‘NovoSeven’), a powerful initiator of hemostasis, is approved for the treatment of bleeding in patients with hemophilia and inhibitors and may also promote hemostasis in patients with normal coagulation. rFVa acts locally at the bleeding site without activating systemic coagulation and may be a valuable therapy during the hyperacute stage of ICH. A randomized, double-blind, placebo-controlled, dose-ranging trial is currently in progress to investigate the potential of rFVIIa as an ultra-early hemostatic therapy to prevent or minimize hematoma growth in ICH patients without coagulopathy.     

Offene Rechtsfragen bei der Gründung Medizinischer Versorgungszentren?

Ohne Zusammenfassung